165 related articles for article (PubMed ID: 36814816)
1. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
Wang L; Zhuang H; Xu X; Zhou J; Jiao Y
Front Oncol; 2023; 13():1129649. PubMed ID: 36814816
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
3. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma.
Yao JJ; Zhang LL; Gao TS; Peng YL; Lawrence WR; Zhang WJ; Zhang F; Zhou GQ; Wang SY; Sun Y
Cancer Biol Ther; 2018; 19(12):1102-1107. PubMed ID: 30081714
[No Abstract] [Full Text] [Related]
4. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
[TBL] [Abstract][Full Text] [Related]
6. Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.
Wang RJ; Ke RQ; Yu YF; Lu GZ; Wu SG
Front Pharmacol; 2024; 15():1366853. PubMed ID: 38576484
[TBL] [Abstract][Full Text] [Related]
7. [Effects of Different Chemoradiotherapy Regimens on Early Survival Outcomes in Patients with Locally Advanced Nasopharyngeal Carcinoma].
Li N; Li P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Sep; 51(5):702-707. PubMed ID: 32975088
[TBL] [Abstract][Full Text] [Related]
8. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
10. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
11. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P
Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518
[TBL] [Abstract][Full Text] [Related]
12. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis.
Lu J; Wei J; Xiao X; Wei Y; Li M; Huang Y; Deng W; Wang H; Gui Z; Liu F; Jiang H; Zhang J; Weng J; Qu S
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2479-2488. PubMed ID: 36577788
[TBL] [Abstract][Full Text] [Related]
14. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study.
Niu X; Liu P; Zhou X; Ou D; Wang X; Hu C
Transl Oncol; 2024 Jan; 39():101797. PubMed ID: 37865048
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
16. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
18. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
[TBL] [Abstract][Full Text] [Related]
19. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]